IPO8 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the IPO8 gene, which encodes the karyopherin importin-8. This pool of HeLa cells, generated by CRISPR/Cas9-mediated genomic disruption, provides a heterogeneous loss-of-function model for studying IPO8-dependent biology without requiring single-cell cloning. The polyclonal format preserves the genetic diversity of the parental line while ensuring consistent gene ablation across the population.
The parental HeLa cell line, originating from a cervical adenocarcinoma, is an immortalized human epithelial line that contains integrated HPV18 sequences and an aneuploid karyotype. HeLa cells are extensively used in cancer research, virology, and signal transduction studies due to their robust proliferation and amenability to genetic manipulation. Their cervical tumor origin makes them particularly relevant for investigating oncogenic signaling pathways and viral?Chost interactions.
Importin-8 functions as a nuclear transport receptor for phosphorylated SMAD complexes, including SMAD1/5/8 and SMAD2/3, which are central to TGF-?? and BMP signaling. IPO8 recognizes these cargo proteins in the cytoplasm and, in a Ran GTPase-controlled process, facilitates their passage through the nuclear pore complex by interacting with nucleoporins such as NUP153 and NUP50. Once nuclear, SMADs drive transcription of downstream targets like ID1, ID2, SERPINE1, and SNAI1. Additionally, IPO8 mediates the import of SR proteins and viral proteins, highlighting its broader role in nucleocytoplasmic trafficking.
In HeLa cells, IPO8 disruption impedes SMAD nuclear accumulation and dampens TGF-??/BMP-induced transcriptional responses. Given that cervical cancers frequently exhibit aberrant TGF-??/BMP signaling, this knockout model enables dissection of importin-8??s contribution to tumor-associated phenotypes??including proliferation, migration, and epithelial?Cmesenchymal transition??without clonal bias. The polyclonal population more closely mimics the heterogeneity of solid tumors, enhancing translational relevance.
Researchers can employ this product in assays such as RT-qPCR for SMAD target genes, SMAD-responsive luciferase reporters, immunofluorescence to track SMAD localization, and phenotypic analyses of cell migration and proliferation. Co-immunoprecipitation experiments can validate disrupted IPO8?CSMAD interactions. The cells are also suitable for investigating viral nuclear import and validating importin-8 as a therapeutic candidate. For further details or technical inquiries, please contact Ascent Research.
